Acadia Pharmaceuticals Stock Analysis

ACADIA Stock Analysis Notes

About 99.0% of the company shares are held by institutions such as insurance companies. The book value of ACADIA Pharmaceuticals was presently reported as 5.42. The company last dividend was issued on the 30th of June 2010. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. Acadia Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 540 people. For more info on ACADIA Pharmaceuticals please contact Stephen JD at 858 558 2871 or go to https://www.acadia.com.

ACADIA Pharmaceuticals Investment Alerts

ACADIA Largest EPS Surprises

View All Earnings Estimates

ACADIA Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

ACADIA Stock Institutional Investors

Note, although ACADIA Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ACADIA Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.35 B.

ACADIA Profitablity

The company has Profit Margin (PM) of 0.25 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.

Management Efficiency

ACADIA Pharmaceuticals has return on total asset (ROA) of 0.0511 % which means that it generated a profit of $0.0511 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3495 %, meaning that it created $0.3495 on every $100 dollars invested by stockholders. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.20. The current year's Return On Capital Employed is expected to grow to 0.28. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 95.2 M, whereas Net Tangible Assets are forecasted to decline to about 403.1 M.

Technical Drivers

As of the 30th of January, ACADIA Pharmaceuticals owns the coefficient of variation of 797.26, and Market Risk Adjusted Performance of 0.231. ACADIA Pharmaceuticals technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices. Please confirm ACADIA Pharmaceuticals mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and information ratio to decide if ACADIA Pharmaceuticals is priced adequately, providing market reflects its prevailing price of 25.13 per share. Given that ACADIA Pharmaceuticals has jensen alpha of 0.1877, we suggest you to validate ACADIA Pharmaceuticals's latest market performance to make sure the company can sustain itself at some future date.

ACADIA Pharmaceuticals Price Movement Analysis

ACADIA Pharmaceuticals Insider Trading Activities

ACADIA Pharmaceuticals Predictive Daily Indicators

ACADIA Pharmaceuticals Corporate Filings

ACADIA Pharmaceuticals Forecast Models

ACADIA Pharmaceuticals' time-series forecasting models are one of many ACADIA Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ACADIA Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

ACADIA Pharmaceuticals Debt to Cash Allocation

ACADIA Pharmaceuticals currently holds 51.99 M in liabilities with Debt to Equity (D/E) ratio of 0.15, which may suggest the company is not taking enough advantage from borrowing. ACADIA Pharmaceuticals has a current ratio of 4.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ACADIA Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

ACADIA Pharmaceuticals Total Assets Over Time

ACADIA Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which ACADIA Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

ACADIA Pharmaceuticals Debt Ratio

8.22

It looks as if most of the ACADIA Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the ACADIA Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of ACADIA Pharmaceuticals, which in turn will lower the firm's financial flexibility.

ACADIA Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how ACADIA Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ACADIA shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ACADIA Pharmaceuticals. By using and applying ACADIA Stock analysis, traders can create a robust methodology for identifying ACADIA entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ACADIA analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ACADIA analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

ACADIA Pharmaceuticals stock analysis indicators help investors evaluate how ACADIA Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ACADIA Pharmaceuticals shares will generate the highest return on investment. By understating and applying ACADIA Pharmaceuticals stock analysis, traders can identify ACADIA Pharmaceuticals position entry and exit signals to maximize returns.

When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.